China Dasheng Biotechnology Company
CDBT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.1M
Close$
$-0.02
124.9% downside
Current Fair Value
124.9% downsideOvervalued by 124.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.10 Million |
|---|---|
| Enterprise Value | $4.14 Million |
| Earnings per Share | $-0.02 |
| Beta | 2.26 |
| Outstanding Shares | 40,976,000 |
Return
| Return on Equity | 3975.74% |
|---|---|
| Return on Assets | -100.12% |
| Return on Invested Capital | 4545.70% |
Valuation & Multiples
| P/E Ratio | -34 |
|---|---|
| PEG | 33.54 |
| Price to Sales | - |
| Price to Book Ratio | -0.1 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -50.22 |
| Enterprise Value to Net Income | -58 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -24.17 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Cycclone Inc.
689 employees
CEO: Michael Nugent
Cycclone Inc., operating with its subsidiaries, specializes in the development, promotion, and distribution of bacteria-derived products. These offerings primarily function as beneficial additives for both agricultural crops and animal f...